These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 24637682)

  • 1. Liposome encapsulation of ciprofloxacin improves protection against highly virulent Francisella tularensis strain Schu S4.
    Hamblin KA; Armstrong SJ; Barnes KB; Davies C; Wong JP; Blanchard JD; Harding SV; Simpson AJ; Atkins HS
    Antimicrob Agents Chemother; 2014 Jun; 58(6):3053-9. PubMed ID: 24637682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The potential of liposome-encapsulated ciprofloxacin as a tularemia therapy.
    Hamblin KA; Wong JP; Blanchard JD; Atkins HS
    Front Cell Infect Microbiol; 2014; 4():79. PubMed ID: 24995163
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization.
    Conlan JW; Shen H; Golovliov I; Zingmark C; Oyston PC; Chen W; House RV; Sjöstedt A
    Vaccine; 2010 Feb; 28(7):1824-31. PubMed ID: 20018266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live attenuated mutants of Francisella tularensis protect rabbits against aerosol challenge with a virulent type A strain.
    Reed DS; Smith LP; Cole KS; Santiago AE; Mann BJ; Barry EM
    Infect Immun; 2014 May; 82(5):2098-105. PubMed ID: 24614653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Inner and Outer Membrane Proteins from
    Post DMB; Slütter B; Schilling B; Chande AT; Rasmussen JA; Jones BD; D'Souza AK; Reinders LM; Harty JT; Gibson BW; Apicella MA
    mBio; 2017 Oct; 8(5):. PubMed ID: 29018123
    [No Abstract]   [Full Text] [Related]  

  • 6. A Francisella tularensis Schu S4 purine auxotroph is highly attenuated in mice but offers limited protection against homologous intranasal challenge.
    Pechous RD; McCarthy TR; Mohapatra NP; Soni S; Penoske RM; Salzman NH; Frank DW; Gunn JS; Zahrt TC
    PLoS One; 2008 Jun; 3(6):e2487. PubMed ID: 18575611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.
    Richard K; Mann BJ; Stocker L; Barry EM; Qin A; Cole LE; Hurley MT; Ernst RK; Michalek SM; Stein DC; Deshong P; Vogel SN
    Clin Vaccine Immunol; 2014 Feb; 21(2):212-26. PubMed ID: 24351755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A ΔclpB mutant of Francisella tularensis subspecies holarctica strain, FSC200, is a more effective live vaccine than F. tularensis LVS in a mouse respiratory challenge model of tularemia.
    Golovliov I; Twine SM; Shen H; Sjostedt A; Conlan W
    PLoS One; 2013; 8(11):e78671. PubMed ID: 24236032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma- dependent mechanism.
    Wayne Conlan J; Shen H; Kuolee R; Zhao X; Chen W
    Vaccine; 2005 Mar; 23(19):2477-85. PubMed ID: 15752834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Francisella tularensis live vaccine strain (LVS) mutant with a deletion in capB, encoding a putative capsular biosynthesis protein, is significantly more attenuated than LVS yet induces potent protective immunity in mice against F. tularensis challenge.
    Jia Q; Lee BY; Bowen R; Dillon BJ; Som SM; Horwitz MA
    Infect Immun; 2010 Oct; 78(10):4341-55. PubMed ID: 20643859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monophosphoryl Lipid A Enhances Efficacy of a Francisella tularensis LVS-Catanionic Nanoparticle Subunit Vaccine against F. tularensis Schu S4 Challenge by Augmenting both Humoral and Cellular Immunity.
    Richard K; Mann BJ; Qin A; Barry EM; Ernst RK; Vogel SN
    Clin Vaccine Immunol; 2017 Mar; 24(3):. PubMed ID: 28077440
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of Francisella tularensis ΔpdpC as a candidate live attenuated vaccine against respiratory challenge by a virulent SCHU P9 strain of Francisella tularensis in a C57BL/6J mouse model.
    Tian D; Uda A; Park ES; Hotta A; Fujita O; Yamada A; Hirayama K; Hotta K; Koyama Y; Azaki M; Morikawa S
    Microbiol Immunol; 2018 Jan; 62(1):24-33. PubMed ID: 29171073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of Schu S4
    Cunningham AL; Mann BJ; Qin A; Santiago AE; Grassel C; Lipsky M; Vogel SN; Barry EM
    Virulence; 2020 Dec; 11(1):283-294. PubMed ID: 32241221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A mutant of Francisella tularensis strain SCHU S4 lacking the ability to express a 58-kilodalton protein is attenuated for virulence and is an effective live vaccine.
    Twine S; Byström M; Chen W; Forsman M; Golovliov I; Johansson A; Kelly J; Lindgren H; Svensson K; Zingmark C; Conlan W; Sjöstedt A
    Infect Immun; 2005 Dec; 73(12):8345-52. PubMed ID: 16299332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral immunization of mice with the live vaccine strain (LVS) of Francisella tularensis protects mice against respiratory challenge with virulent type A F. tularensis.
    KuoLee R; Harris G; Conlan JW; Chen W
    Vaccine; 2007 May; 25(19):3781-91. PubMed ID: 17346863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection.
    Wong JP; Yang H; Blasetti KL; Schnell G; Conley J; Schofield LN
    J Control Release; 2003 Oct; 92(3):265-73. PubMed ID: 14568408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of Francisella tularensis Schu S4 defined mutants as live-attenuated vaccine candidates.
    Santiago AE; Mann BJ; Qin A; Cunningham AL; Cole LE; Grassel C; Vogel SN; Levine MM; Barry EM
    Pathog Dis; 2015 Aug; 73(6):ftv036. PubMed ID: 25986219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The D-alanyl-d-alanine carboxypeptidase enzyme is essential for virulence in the Schu S4 strain of Francisella tularensis and a dacD mutant is able to provide protection against a pneumonic challenge.
    Kijek TM; Mou S; Bachert BA; Kuehl KA; Williams JA; Daye SP; Worsham PL; Bozue JA
    Microb Pathog; 2019 Dec; 137():103742. PubMed ID: 31513897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain.
    Skyberg JA; Rollins MF; Samuel JW; Sutherland MD; Belisle JT; Pascual DW
    Infect Immun; 2013 Sep; 81(9):3099-105. PubMed ID: 23774604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular immune responses to aerosol challenge with Francisella tularensis in mice inoculated with live vaccine candidates of varying efficacy.
    Shen H; Harris G; Chen W; Sjostedt A; Ryden P; Conlan W
    PLoS One; 2010 Oct; 5(10):e13349. PubMed ID: 20967278
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.